Skip to main content
Top
Published in: Archives of Virology 11/2014

01-11-2014 | Original Article

Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758

Authors: Qian Yang, Suzhen Fu, Jie Wang

Published in: Archives of Virology | Issue 11/2014

Login to get access

Abstract

Chronic infection with hepatotropic viruses is the main cause of chronic liver disease and cirrhosis worldwide. Toll-like receptor 3 (TLR3) and Toll-like receptor 7 (TLR7) are pathogen-recognition receptors that are expressed on innate immune cells. They recognize viral RNA, which induces their activation, with a subsequent increase in type I interferon transcription. Hepatitis C virus (HCV) infection inhibits the expression of TLR3 and TLR7; however, the mechanism by which this occurs is unclear. MicroRNAs (miRNAs) are small RNAs that posttranscriptionally regulate gene expression. Their aberrant expression is commonly correlated with disease status, as is the case with HCV infection. Here, we found that miR-758 levels were increased in patients with HCV infection and were correlated with TLR3 and TLR7 expression levels in the patients with HCV infection, and bioinformatics analysis predicted that TLR3 and TLR7 are targets of miR-758. Therefore, we postulate that HCV may increase the level of miR-758, which inhibits the expression of TLR3 and TLR7, resulting in a loss of antiviral effect. In order to test our hypothesis, we constructed an HCV core protein expression plasmid and used it to transfect liver cells. The results showed that HCV infection increased miR-758 levels and decreased TLR3/TLR7 expression. Furthermore, using RT-PCR and luciferase reporter analysis, we found that miR-758 targets TLR3 and TLR7, with a subsequent decrease in IFNα and IFNβ production. In conclusion, our results highlight the upregulation of miR-758 expression by HCV as a novel mechanism contributing to downregulation of TLR3 and TLR7 in patients with HCV infection.
Literature
1.
go back to reference Benvegnu L, Gios M, Boccato S, Alberti A (2004) Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53:744–749PubMedCrossRefPubMedCentral Benvegnu L, Gios M, Boccato S, Alberti A (2004) Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53:744–749PubMedCrossRefPubMedCentral
2.
go back to reference Lok AS, Heathcote EJ, Hoofnagle YH (2001) Managment of hepatitis B: 2000—summary of a workshop. Gastroenterology 120:1828–1853PubMedCrossRef Lok AS, Heathcote EJ, Hoofnagle YH (2001) Managment of hepatitis B: 2000—summary of a workshop. Gastroenterology 120:1828–1853PubMedCrossRef
3.
go back to reference (1999) EASL international consensus conference on hepatitis C: Paris, 26–28 February 1999 consensus statement. J Hepatol 30:956–961 (1999) EASL international consensus conference on hepatitis C: Paris, 26–28 February 1999 consensus statement. J Hepatol 30:956–961
4.
go back to reference Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T (1999) Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 116:378–386PubMedCrossRef Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, Ratziu V, Opolon P, Poynard T (1999) Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. Gastroenterology 116:378–386PubMedCrossRef
5.
go back to reference International Interferon-alfa Hepatocellular Carcinoma Study Group (1998) Effect of interferon-a on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 351:1535–1539CrossRef International Interferon-alfa Hepatocellular Carcinoma Study Group (1998) Effect of interferon-a on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 351:1535–1539CrossRef
6.
go back to reference Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J (2000) Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131–1137PubMedCrossRef Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J (2000) Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131–1137PubMedCrossRef
7.
go back to reference Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, Goode J, Lin P, Mann N, Mudd S, Crozat K, Sovath S, Han J, Beutler B (2003) Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424:743–748PubMedCrossRef Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, Goode J, Lin P, Mann N, Mudd S, Crozat K, Sovath S, Han J, Beutler B (2003) Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424:743–748PubMedCrossRef
8.
go back to reference Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529–1531PubMedCrossRef Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529–1531PubMedCrossRef
9.
go back to reference Mohammed KI, Adel LA, Ali-Eldin FA, Eladawy S (2013) Expression of Toll like receptors 3 & 7 in peripheral blood from patients with chronic hepatitis C virus infection and their correlation with interferon-alpha. Egypt J Immunol 20:13–22PubMed Mohammed KI, Adel LA, Ali-Eldin FA, Eladawy S (2013) Expression of Toll like receptors 3 & 7 in peripheral blood from patients with chronic hepatitis C virus infection and their correlation with interferon-alpha. Egypt J Immunol 20:13–22PubMed
10.
go back to reference Sato K, Ishikawa T, Okumura A, Yamauchi T, Sato S, Ayada M, Matsumoto E, Hotta N, Oohashi T, Fukuzawa Y, Kakumu S (2007) Expression of Toll-like receptors in chronic hepatitis C virus infection. J Gastroenterol Hepatol 22(10):1627–1632PubMedCrossRef Sato K, Ishikawa T, Okumura A, Yamauchi T, Sato S, Ayada M, Matsumoto E, Hotta N, Oohashi T, Fukuzawa Y, Kakumu S (2007) Expression of Toll-like receptors in chronic hepatitis C virus infection. J Gastroenterol Hepatol 22(10):1627–1632PubMedCrossRef
11.
go back to reference Huang YW, Lin SC, Wei SC, Hu JT, Chang HY, Huang SH, Chen DS, Chen PJ, Hsu PN, Yang SS, Kao JH (2013) Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy. Antivir Ther 18(7):877–884PubMedCrossRef Huang YW, Lin SC, Wei SC, Hu JT, Chang HY, Huang SH, Chen DS, Chen PJ, Hsu PN, Yang SS, Kao JH (2013) Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy. Antivir Ther 18(7):877–884PubMedCrossRef
12.
go back to reference Roberts AP, Lewis AP, Jopling CL (2011) The role of microRNAs in viral infection. Prog Mol Biol Transl Sci 102:101–139PubMedCrossRef Roberts AP, Lewis AP, Jopling CL (2011) The role of microRNAs in viral infection. Prog Mol Biol Transl Sci 102:101–139PubMedCrossRef
13.
go back to reference Shrivastava S, Petrone J, Steele R, Lauer GM, Di Bisceglie AM, Ray RB (2013) Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology 58:863–871PubMedCrossRefPubMedCentral Shrivastava S, Petrone J, Steele R, Lauer GM, Di Bisceglie AM, Ray RB (2013) Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology 58:863–871PubMedCrossRefPubMedCentral
14.
18.
go back to reference Sarnow P, Jopling CL, Norman KL, Schutz S, Wehner KA (2006) Micro-RNAs: expression, avoidance and subversion by vertebrate viruses. Nat Rev Microbiol 4:651–659PubMedCrossRef Sarnow P, Jopling CL, Norman KL, Schutz S, Wehner KA (2006) Micro-RNAs: expression, avoidance and subversion by vertebrate viruses. Nat Rev Microbiol 4:651–659PubMedCrossRef
19.
go back to reference Conrad KD, Niepmann M (2013) The role of microRNAs in hepatitis C virus RNA replication. Arch Virol (Epub ahead of print) Conrad KD, Niepmann M (2013) The role of microRNAs in hepatitis C virus RNA replication. Arch Virol (Epub ahead of print)
20.
go back to reference Ramirez CM, Dávalos A, Goedeke L, Salerno AG, Warrier N, Cirera-Salinas D, Suárez Y, Fernández-Hernando C (2011) MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol 31(11):2707–2714PubMedCrossRefPubMedCentral Ramirez CM, Dávalos A, Goedeke L, Salerno AG, Warrier N, Cirera-Salinas D, Suárez Y, Fernández-Hernando C (2011) MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol 31(11):2707–2714PubMedCrossRefPubMedCentral
21.
go back to reference Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23:307–336PubMedCrossRef Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23:307–336PubMedCrossRef
Metadata
Title
Hepatitis C virus infection decreases the expression of Toll-like receptors 3 and 7 via upregulation of miR-758
Authors
Qian Yang
Suzhen Fu
Jie Wang
Publication date
01-11-2014
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 11/2014
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-014-2167-3

Other articles of this Issue 11/2014

Archives of Virology 11/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.